BioSight - About the company
BioSight is an acquired company based in Karmiel (Israel), founded in 2000. It operates as a Developer of therapeutics for oncology & hematological disorders. BioSight has raised $59M in funding from investors like Israel Biotech Fund, Primera Capital and Arkin Holdings. The company has 3714 active competitors, including 1282 funded and 870 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Sana Biotechnology.
Company Details
Developer of therapeutics for oncology & hematological disorders. The company's lead product is aspacytarabine (BST-236) an anti-metabolite for Adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Key Metrics
Founded Year
2000
Location
Karmiel, Israel
Stage
Acquired
Total Funding
$59M in 3 rounds
Latest Funding Round
Investors
Ranked
517th among 3714 active competitors
Employee Count
3 as on May 31, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Acquired by Advaxis (Jul 06, 2021)
BioSight's acquisition details
BioSight got acquired by Advaxis on Jul 06, 2021.
Click here to take a look at BioSight's acquisition in detail
Sign up to download BioSight's company profile
BioSight's funding and investors
BioSight has raised a total funding of $59M over 3 rounds. Its first funding round was on May 16, 2016. Its latest funding round was a Series C round on Dec 02, 2020 for $*****. 6 investors participated in its latest round. BioSight has 10 institutional investors.
Here is the list of recent funding rounds of BioSight:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 02, 2020 | 6472412 | Series C | 3331333 | 5020894 | 5073929 | 8448348 |
Mar 11, 2020 | 9529728 | Series C | 4635263 | 8323786 | 9637206 | |
May 16, 2016 | 9931454 | Series A | 2738923 | 2909087 | 7283335 |
Access funding benchmarks and valuations. Sign up today!View details of BioSight's funding rounds and investors
BioSight's founders and board of directors
Founder? Claim ProfileBioSight's employee count trend
BioSight has 3 employees as of May 26. Here is BioSight's employee count trend over the years:
Uncover BioSight's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
BioSight's Competitors and alternates
Top competitors of BioSight include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of BioSight, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
4th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
7th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
8th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
9th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
10th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
517th | Developer of therapeutics for oncology & hematological disorders | $59M | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on BioSight's competitors? Click here to see the top ones
BioSight's Investments and acquisitions
BioSight has acquired Advaxis. BioSight has not made any investments as of now.News related to BioSight
Filter this listMedia has covered BioSight for 1 event in last 1 year, It was about company updates.
•
Biosaitu announces Tubulis signs antibody licensing agreement to advance ADC therapy developmentBusiness Wire•Sep 16, 2025•BioSight
•
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger AgreementGlobeNewswire•Jul 27, 2023•Ayala Pharma, BioSight
•
•
•
•
•
•
Biosight Closes $46M Series C Financing to Advance Clinical Oncology ProgramsGlobeNewswire•Dec 02, 2020•BioSight, Israel Biotech Fund
•
•
Biosight Strengthens Board of Directors with Appointment of Industry Executive Gary Gordon, M.D, Ph.D.GlobeNewswire•May 18, 2020•BioSight, AbbVie
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about BioSight
Explore our recently published companies
- Saalfo Tech - Mysuru based, 1990 founded, Unfunded company
- Tolia - Thane based, 1979 founded, Unfunded company
- Uvtcpl - India based, Unfunded company
- Diamondexch99 - Unfunded company
- Krishna's Herbal & Ayurveda - Jodhpur based, 2007 founded, Funding Raised company
- Dash - Atlanta based, 2025 founded, Unfunded company
